A homologous-targeting "nanoconverter" with variable size for deep tumor penetration and immunotherapy. Issue 9 (23rd February 2021)
- Record Type:
- Journal Article
- Title:
- A homologous-targeting "nanoconverter" with variable size for deep tumor penetration and immunotherapy. Issue 9 (23rd February 2021)
- Main Title:
- A homologous-targeting "nanoconverter" with variable size for deep tumor penetration and immunotherapy
- Authors:
- Cong, Cong
Jiaxin, Bian
Liu, Xiaokang
Zhang, Xinyue
Fu, Yihan
Li, Zhuo
Xu, Zichuang
Wei, Shipan
Wang, Desong
Gao, Dawei - Abstract:
- Abstract : Schematic of the fabrication of PTX/PDA@M-C6 for deep penetration, photothermal response release, specific tumor apoptosis and immunotherapy. Abstract : Tumor-associated immunosuppression, as a key barrier, prevents immunotherapy-resistant tumors. In this study, an ingenious "nanoconverter" was designed to convert immunosuppression into immunoactivation, which was a C6-ceramide (C6)-modified tumor cytomembrane-coated polydopamine-paclitaxel system (PTX/PDA@M-C6). The co-administration of C6-ceramide and tumor cytomembrane changed an adaptive immune state to an activation state, which induced a robust antigen presentation ability of tumor-infiltrating dendritic cells to activate T1 helper cells and cytotoxic T lymphocytes. Meanwhile, C6-ceramide regulated the phenotype of macrophages via the reactive oxygen species pathway, which resulted in the conversion of M2-like macrophages by infiltration within tumors into M2-like macrophages, and therefore, M2-like macrophage-mediated immunosuppression was weakened distinctly. The "nanoconverter"-mediated conversion process upregulated the expression of related immune factors including interleukin-12, interleukin-6, tumor necrosis factor-α and interferon-γ and executed positive anti-tumor effects. In addition, under the protection of tumor-homologous cytomembrane, the "nanoconverter" exhibited excellent delivery efficiency (23.22%), and subsequently, accumulated special structural "nanoconverter" could break down intoAbstract : Schematic of the fabrication of PTX/PDA@M-C6 for deep penetration, photothermal response release, specific tumor apoptosis and immunotherapy. Abstract : Tumor-associated immunosuppression, as a key barrier, prevents immunotherapy-resistant tumors. In this study, an ingenious "nanoconverter" was designed to convert immunosuppression into immunoactivation, which was a C6-ceramide (C6)-modified tumor cytomembrane-coated polydopamine-paclitaxel system (PTX/PDA@M-C6). The co-administration of C6-ceramide and tumor cytomembrane changed an adaptive immune state to an activation state, which induced a robust antigen presentation ability of tumor-infiltrating dendritic cells to activate T1 helper cells and cytotoxic T lymphocytes. Meanwhile, C6-ceramide regulated the phenotype of macrophages via the reactive oxygen species pathway, which resulted in the conversion of M2-like macrophages by infiltration within tumors into M2-like macrophages, and therefore, M2-like macrophage-mediated immunosuppression was weakened distinctly. The "nanoconverter"-mediated conversion process upregulated the expression of related immune factors including interleukin-12, interleukin-6, tumor necrosis factor-α and interferon-γ and executed positive anti-tumor effects. In addition, under the protection of tumor-homologous cytomembrane, the "nanoconverter" exhibited excellent delivery efficiency (23.22%), and subsequently, accumulated special structural "nanoconverter" could break down into smaller nanoparticles for deep penetration into the tumor tissue under a NIR laser. Ultimately, chemo/thermal therapy-assisted immunotherapy completely eliminated the tumors of tumor-bearing mice, and a potent memory response relying on effector memory T cells still persisted to protect against tumor relapse after the end of treatment. The "nanoconverter" serves as a promising nanodrug delivery system for the conversion of immunosuppression and enhanced chemo/thermal therapy. Therefore, the highly cumulative "nanoconverter" has great potential for promoting the effect and clinical application of immunotherapy. … (more)
- Is Part Of:
- Journal of materials chemistry. Volume 9:Issue 9(2021)
- Journal:
- Journal of materials chemistry
- Issue:
- Volume 9:Issue 9(2021)
- Issue Display:
- Volume 9, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 9
- Issue:
- 9
- Issue Sort Value:
- 2021-0009-0009-0000
- Page Start:
- 2323
- Page End:
- 2333
- Publication Date:
- 2021-02-23
- Subjects:
- Materials -- Periodicals
Chemistry, Analytic -- Periodicals
Biomedical materials -- Research -- Periodicals
543.0284 - Journal URLs:
- http://pubs.rsc.org/en/journals/journalissues/tb# ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/d0tb02908d ↗
- Languages:
- English
- ISSNs:
- 2050-750X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5012.205200
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 16129.xml